Meet the Team

  • Takashi Takenoshita

    31 years in pharmaceutical strategy and CEO roles

    19 years at McKinsey where he was a partner and co-led the European and Japanese Pharmaceutical Practice

    Led over 100 projects for 14 pharmaceutical companies; 30+ products

    12 years in CEO and GM role: CEO, Shionogi Europe; Head of International, Arena; Interim European GM, Invivyd; CEO, Dark Blue Therapeutics; CEO Senya Therapeutics

    View on LinkedIn

  • Sandy Nielsen

    25 years of experience in market access

    Head senior market access positions at IQVIA, Arena, Ferring

    In-depth experience of HEOR, real world evidence and market access strategy

    View on LinkedIn

  • Suzanne Einmhal

    20+ years of experience as consultant in regulatory affairs and clinical development.

    Specialized in EU regulatory affairs, strategy, pre-submission activities and registration

    Expertise in labels and data requirement

    View on LinkedIn

  • Luca Bertolin

    10 years of experience in top pharma firms including Roche, Celgene, BMS and AbbVie.

    Expert in product positioning, sales forecast and commercial activity planning

    In-depth understanding of partner market in Europe

    View on LinkedIn

LivBio’s distinctive offer

CEO viewpoint: we work with CEOs and CFOs. We are corporate. Not commercial. We understand the constraints each business faces and trade-offs that companies need to make.

Cross-functional: we are experienced in bridging development, regulatory, supply, medical, market access and commercial. This is what it takes to develop a CEO level recommendation.

Fully-trained strategic consultants with significant operational experience. Strategic insight grounded in operational reality.

Subject matter expertise: We review a number of clinical-stage assets for clinical stage companies every year. We build on learnings from similar situations while paying attention to specificities of each case. We are well aware of the latest trends and historical patterns.

Value maximising strategy: true upside and realistic assessment of possibilities based on deep market insight and operational experience.

Independent thinking: we are 100% focused on shareholder value and CEO/CFO viewpoint. No bias towards any outcome (e.g., in-house build or license-out)

Value-for-money: We are set up to support pre-revenue stage enterprises with little overhead and resources shared across multiple projects. We are partnership of consultants who get paid for the time we put in.